1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, January 2018 (p4)

Cancer Analysis & Statistics in European Union, January 2018 (p4)

91-120 of about 100 reports

Drug Overview: ipatasertib

Drug Overview: ipatasertib

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: Jevtana

Drug Analysis: Jevtana

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewJevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Industries : Therapy, Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: darolutamide

Drug Analysis: darolutamide

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDarolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: DCVAC/PCa

Drug Analysis: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Masitinib

Drug Analysis: Masitinib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMasitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : European Union, United States
Drug Overview: Tecentriq

Drug Overview: Tecentriq

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Drug Overview: Masitinib

Drug Overview: Masitinib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMasitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : European Union, United States
Drug Overview: DCVAC/PCa

Drug Overview: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Xofigo

Drug Overview: Xofigo

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Overview: Zytiga

Drug Overview: Zytiga

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewZytiga (abiraterone acetate; Johnson&Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Overview: darolutamide

Drug Overview: darolutamide

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Rubraca

Drug Overview: Rubraca

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewRubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Industries : Therapy, Cancer, Pathology, Oncology
  • Countries : United States, European Union
Drug analysis: Erbitux

Drug analysis: Erbitux

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug analysis: Lonsurf

Drug analysis: Lonsurf

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewLonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects. It is composed of trifluridine, an antineoplastic nucleoside ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Napabucasin

Drug analysis: Napabucasin

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewNapabucasin (Dainippon Sumitomo) is designed to selectively and simultaneously inhibit multiple key pathways associated with tumor growth and development by targeting the STAT3 transcription ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Cyramza

Drug analysis: Cyramza

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewCyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellula ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Encorafenib

Drug analysis: Encorafenib

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewEncorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E. The drug was developed ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union
Gastric Cancer Forecast and Market Analysis to 2024

Gastric Cancer Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • December 2017

Disease OverviewGastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Vectibix

Drug analysis: Vectibix

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewVectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents ...

  • Industries : Medical Biotechnology, Cancer, Therapy, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug analysis: Cotellic

Drug analysis: Cotellic

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewCotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Drug analysis: Stivarga

Drug analysis: Stivarga

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewStivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor recepto ...

  • Industries : Diagnostic Imaging, Pathology, Cancer
  • Countries : United States, Japan, European Union
Colorectal Cancer Forecast and Market Analysis to 2036

Colorectal Cancer Forecast and Market Analysis to 2036

  • $ 22000
  • Industry report
  • December 2017

Disease OverviewColorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiato ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Drug analysis: Avastin

Drug analysis: Avastin

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewAvastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Binimetinibi

Drug analysis: Binimetinibi

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewBinimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, European Union
Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML)

  • $ 22000
  • Industry report
  • December 2017

Disease OverviewChronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Gilotrif

Drug Analysis: Gilotrif

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewGilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: Imfinzi

Drug Analysis: Imfinzi

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewAstraZeneca’s Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: Bavencio

Drug Analysis: Bavencio

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewBavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • October 2017

DISEASE OVERVIEWMultiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • June 2017

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on